Other substances

Thalidomide

A piperidinyl isoindole.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Thalidomide is a piperidinyl isoindole compound with anti-inflammatory, immunomodulatory, anti-angiogenic, and anti-neoplastic properties. It is used for treatment of multiple myeloma or cutaneous manifestations of leprosy. It is teratogenic, however (DrugBank, PubChem). It is on the World Health Organization Model List of Essential Medicines.

Thalidomide on Wikipedia

Marketed as

CONTERGAN; DISTAVAL; K-17; PRO-BAN M; SEDALIS; SOFTENON; TALIMOL; THALED; THALIDOMIDE; CELGENE; THALIDOMID

C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Thalidomide Combined with Short-term Low-Dose Glucocorticoid Therapy for the Treatment of Severe COVID-19: A Case-Series Study Severe severity Small molecule Critical severity Case series	Severe to critical COVID-19 patients	3.20	Observed faster SARS-CoV-2 negative conversion, shorter length of hospital stay, or reduced need of mechanical ventilation in critical COVID-19 patients. Treatment with thalidomide, together with low-dose glucocorticoid therapy, was suggested to be effective in improving critical COVID-19 patients' prognosis. It could act via cytokine production suppression. Sample size: 6 + 6 control. Dosage: 100 mg daily for 7+ days.	Dec/10/2020

AI-suggested references

Link	Publication date
Thalidomide Should Be Tested as a Therapeutic Option in COVID-19 Pneumonia.	Oct/09/2021
Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019	Jun/23/2020
Network bioinformatics analysis provides insight into drug repurposing for COVID-19.	Mar/30/2021
Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.	Oct/13/2020
Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019.	Jun/22/2020
Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action	Mar/15/2021
Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs	Jan/06/2021
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study	Sep/06/2020
Topological indices and QSPR/QSAR analysis of some antiviral drugs being investigated for the treatment of COVID-19 patients.	Dec/31/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04273529	The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia	Unknown status	Phase 2	Feb/20/2020	Jun/30/2020
Alternative id - 20200214-COVID-19-M-T Interventions - Drug: thalidomide\|Drug: placebo Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 100 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to Clinical recoveryTime to Clinical Recovery (TTCR)\|All cause mortality\|Frequency of respiratory progression\|Time to defervescence
NCT04273581	The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19	Unknown status	Phase 2	Feb/18/2020	May/30/2020
Alternative id - 20200214-COVID-19-S-T Interventions - Drug: placebo\|Drug: Thalidomide Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 40 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to Clinical Improvement (TTCI)\|Clinical status\|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours\|All cause mortality\|Duration (days) of mechanical ventilation\|Duration (days) of extracorporeal membrane oxygenation\|Duration (days) of supplemental oxygenation\|Length of hospital stay (days)\|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens\|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.\|Frequency of serious adverse drug events\|Serum TNF-α, IL-1β, IL-2, IL-6, IL-7, IL-10, GSCF, IP10#MCP1, MIP1α and other cytokine expression levels before and after treatment

Export (.csv)